George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

Is Tilray Finally a Buy?

Is Tilray's strong first-quarter report a good reason to buy this flagging pot stock?